Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice

Arthritis and Rheumatology

Volumn 67, Issue 4, 2015, Pages 893-902

  Nishimura, Keisuke ^a   Saegusa, Jun ^a   Matsuki, Fumichika ^a   Akashi, Kengo ^a   Kageyama, Goichi ^a   Morinobu, Akio ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; FILGOTINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; SODIUM CHLORIDE; TOFACITINIB; ZYMOSAN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OSMOTIC PUMP; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RECIPIENT; RHEUMATOID ARTHRITIS; SUPPRESSOR CELL; ANIMAL; ARTHRITIS, EXPERIMENTAL; CD4+ T LYMPHOCYTE; DRUG EFFECTS; IMMUNOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; MICE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84925797532     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39007     Document Type: Article

References (37)

1. Firestein GS,. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
2. Lutzky V, Hannawi S, Thomas R,. Cells of the synovium in rheumatoid arthritis: dendritic cells. Arthritis Res Ther 2007; 9: 219.
3. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor. Science 2003; 302: 875-8.
4. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64: 617-29.
5. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19.
6. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI,. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989-99.
7. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003; 170: 270-8.
8. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S,. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507-13.
9. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P,. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003; 24: 302-6.
10. Kusmartsev S, Gabrilovich DI,. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 2003; 74: 186-96.
11. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI,. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-802.
12. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008; 111: 5457-66.
13. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-44.
14. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC,. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13: 721s-6s.
15. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-89.
16. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-307.
17. Voisin MB, Buzoni-Gatel D, Bout D, Velge-Roussel F,. Both expansion of regulatory GR1+ CD11b+ myeloid cells and anergy of T lymphocytes participate in hyporesponsiveness of the lung-associated immune system during acute toxoplasmosis. Infect Immun 2004; 72: 5487-92.
18. + population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204: 1463-74.
19. Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol 2012; 188: 1136-46.
20. Fujii W, Ashihara E, Hirai H, Nagahara H, Kajitani N, Fujioka K, et al. Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J Immunol 2013; 191: 1073-81.
21. Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, Sakihama T, et al. A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J Exp Med 2005; 201: 949-60.
22. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003; 426: 454-60.
23. Misaki K, Morinobu A, Saegusa J, Kasagi S, Fujita M, Miyamoto Y, et al. Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice. Arthritis Res Ther 2011; 13: R77.
24. Zhang L, Zhang Z, Zhang H, Wu M, Wang Y,. Myeloid-derived suppressor cells protect mouse models from autoimmune arthritis via controlling inflammatory response. Inflammation 2014; 37: 670-7.
25. Oh K, Seo MW, Kim IG, Hwang YI, Lee HY, Lee DS,. CP-690550 treatment ameliorates established disease and provides long-term therapeutic effects in an SKG arthritis model. Immune Netw 2013; 13: 257-63.
26. Li Z, Pang Y, Gara SK, Achyut BR, Heger C, Goldsmith PK, et al. Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGFβ in breast cancer progression. Int J Cancer 2012; 131: 2584-95.
27. Jiao Z, Hua S, Wang W, Wang H, Gao J, Wang X,. Increased circulating myeloid-derived suppressor cells correlated negatively with Th17 cells in patients with rheumatoid arthritis. Scand J Rheumatol 2013; 42: 85-90.
28. Egelston C, Kurko J, Besenyei T, Tryniszewska B, Rauch TA, Glant TT, et al. Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis. Arthritis Rheum 2012; 64: 3179-88.
29. Pan PY, Wang GX, Yin B, Ozao J, Ku T, Divino CM, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111: 219-28.
30. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I,. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337-43.
31. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S,. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007; 67: 10019-26.
32. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S,. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179: 977-83.
33. Grossman WJ, Verbsky JW, Yang L, Berg LJ, Fields LE, Chaplin DD, et al. Dysregulated myelopoiesis in mice lacking Jak3. Blood 1999; 94: 932-9.
34. Yan D, Yang Q, Shi M, Zhong L, Wu C, Meng T, et al. Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway. Eur J Immunol 2013; 43: 2943-55.
35. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012; 21: 822-35.
36. Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 2014; 73: 2192-8.
37. Charles JF, Hsu LY, Niemi EC, Weiss A, Aliprantis AO, Nakamura MC,. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest 2012; 122: 4592-605.